Infection with high-risk human papillomavirus (HR-HPV) is transient and clears on its own in majority of the women. Only a few women who have persistent infection may finally develop cervical intraepithelial neoplasia (CIN) or cervical cancer in later years. The risk of progression in the HR-HPV-positive women with normal cervix or low-grade lesion on colposcopy and histopathology at baseline is less studied. We performed a longitudinal study on 650 HR-HPV-positive women with colposcopy and/or histopathology-proved normal or CIN1 diagnosis at baseline to assess the cumulative risk of development of high-grade CIN. After a mean follow-up of 2.1 person years of observation (PYO) (range 0.1-5.1), the cumulative incidence of CIN21 (6.4%; 3.0/100 PYO) was significantly higher in women who had persistent HR-HPV infection compared to those who cleared the infection (adjusted HR 6.28; 95% CI 2.87-13.73). The risk of viral persistence in women aged 50-60 years was two times higher compared to women aged 40-49 years and three times higher compared to women aged 30-39 years. The probability of having persistent infection increased progressively with higher viral load at baseline (adjusted HR 3.29, 95% CI 2.21-4.90 for RLU 100; adjusted HR 2.69, 95% CI 1.71-4.22 for RLU 10-100). Women with increasing viral load at followup had four times higher risk of developing CIN2 or worse lesions as compared to those with decreasing load (20.9% vs 4.8%; p < 0.001). In the context of developing countries where cytology or genotyping triaging is not feasible, colposcopy referral of HR-HPV-positive women with advancing age, viral persistence, and increasing viral load may be considered.
at the baseline. The study population was derived from the 30-to 60-year-old women attending a community-based cervical cancer screening demonstration project conducted by Chittaranjan National Cancer Institute (CNCI), Kolkata, between April 2010 and March 2015. The HPV-positive women who were normal on colposcopy and/or biopsy or had a histological diagnosis of CIN1at baseline were included. The women with biopsy-proved CIN2 or worse lesions (CIN21) at baseline were treated and excluded from the study. The cohort was followed up yearly with colposcopy and biopsy as the reference tests. The study end point was a histological diagnosis of CIN2, CIN3, adenocarcinoma in-situ (AIS), or invasive cancer at any follow-up visit.
Written informed consent was obtained from all the women agreeing to participate in the study. The research study protocol was reviewed and approved by the Human Research Ethics Committee of CNCI.
Procedures at baseline
The details of the recruitment of women and the screening process have been discussed in our earlier publication. 7 In brief, nonpregnant women between 30 and 60 years of age with intact uterus and no previous history of cervical neoplasia were screened using the HCII test to detect the presence of any of the 13 oncogenic types of HPV. The women who tested positive on HCII test were recalled for colposcopy. Cervical biopsies were obtained from any colposcopically visible lesion and from the anterior lip of the cervix (close to the squamocolumnar junction) if no lesion was visible. Women detected to have CIN21 on biopsy were treated appropriately. Women who had a baseline final diagnosis of normal or CIN1 were advised yearly follow-up.
Procedures at follow-up
The women were invited for yearly follow-up with HCII test and colposcopy till they were diagnosed with high-grade cervical disease and treated for that. An active follow-up mechanism was initiated to recall the women around the time of their scheduled visit either by contacting them over telephone or by sending community health workers to their homes. To improve compliance, the women were provided with travel support to attend the follow-up clinics set-up at the primary health centers. If any woman missed the scheduled follow-up, she was advised to attend the clinics on any working day convenient to her.
At each follow-up visit, HCII test and colposcopy were performed. If any abnormality was detected on colposcopy, cervical biopsy was directed from the area(s) showing worst changes. Cervical biopsies were obtained from the anterior lip close to the squamocolumnar junction of the cervix even if no lesions were detected on colposcopy. Women detected to have histology proved CIN21 at any of the follow-up visits were treated and were excluded from further follow-up. Some of the women underwent treatment due to high-grade lesions suspected on colposcopy (see and treat) though the histology showed low-grade lesions and they were also eliminated from subsequent follow-up.
HCII test was performed at the CNCI laboratory. Cervical samples were designated as positive if the relative light unit (RLU) reading of the assay was equal to or greater than the mean of the positive control (PC) values (RLU/PC ratio of 1). All the biopsy specimens were processed and examined at the department of pathology of CNCI, Kolkata. All the histology slides with CIN11 diagnosis and 10% of the normal slides were reviewed at the Department of Gynecological Pathology at the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Statistical analysis
The baseline sociodemographic and reproductive characteristics of the women were presented as proportions. The comparison of these characteristics between the women who returned for follow-up and those who did not was done using the v 2 test. The two primary outcomes assessed in the analysis were HPV persistence and incidence of CIN21 during follow-up among women found HPV positive with normal or CIN1 final diagnosis at baseline. For both primary outcomes, the HPV status and final diagnosis of the women at their last follow-up visits were used to define the outcomes. For the CIN21 outcome, the last follow-up visit for the CIN21 cases corresponded to the incidence date because after diagnosis, these women exit the study and rejoined the routine healthcare for management. The effect of the women's baseline characteristics, HPV viral load and final diagnosis on the HPV persistence and additionally HPV infection status at last follow-up on CIN21 incidence, was evaluated using hazard ratios (HRs) and their 95% confidence intervals (CIs) obtained from the Cox proportional hazards regression analysis. For all participants, the person-years of observation (PYO) for both primary outcomes in this analysis were What's new? What is the best screening method for cervical cancer? It depends on the resources available. In areas where cytological testing is prohibitively expensive, researchers look to other risk factors. These authors investigated whether persistence of HPV infection could effectively predict cancer risk. They studied 650 women with high-risk HPV infection for 2 years to determine their risk of developing high-grade CIN. Three-fourth of the women cleared the infection, they found, and did not develop high-grade CIN, but those whose viral load increase during the follow-up period had four times higher risk of developing CIN2 or higher.
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calculated starting from the date of baseline screening to the date of last follow-up. All the demographic and other factors studied were included in the multivariate regression analyses as appropriate for each of the primary outcomes. Stata 13.0 (StataCorp LP, Texas, USA) was used to carry out the analyses.
Results

Study population
Total 43,325 women were screened by HCII test in the demonstration project and 2,045 (4.7%) of them were positive for HR-HPV. The baseline diagnosis by colposcopy and/or biopsy was available for 78.6% (1,608/2,045) women. Women without any baseline diagnosis (N 5 437), because they either were noncompliant to colposcopy or had inconclusive biopsy report, and those with a CIN21 diagnosis (N 5 220) on baseline histopathology were excluded from the study. The remaining 1,388 women were enrolled to the study, of which 769 were diagnosed as normal and 619 as CIN1 (Fig. 1) .
The mean age of the women at enrollment was 39.1 6 8.3 years and 23.3% (324/1,388) of them were postmenopausal. In spite of our active follow-up efforts, only 650 (46.8%) women attended at least one follow-up. There was no observed difference in the characteristics of the women compliant and noncompliant to follow-up except for the baseline final diagnosis (Table 1) . Follow-up compliance rate was higher in the women with the baseline diagnosis of CIN1 compared to those with normal diagnosis (p < 0.001).The viral persistence and the natural history of the disease at follow-up could naturally be studied only in the cohort of women (N 5 650) attending at least one follow-up. The mean number of follow-up visits for these women was 1.48 per woman.
Viral persistence in the HR-HPV-positive women
A total of 626 women with normal or CIN1 diagnosis at baseline were considered for analysis of HPV persistence. HCII test could not be done in 24 women during the follow-up visits. The overall mean duration of follow-up was 2.0 PYO (range 0.1-5.1). Majority of the women (74.4%; 466/626) cleared the infection in a mean follow-up time of 2.1 PYO (range 0.1-5.1). HPV infection persisted in 25.6% (160/626) women. The risk of viral persistence increased with increasing age of the women ( Table 2 ). The risk was three times higher in the age group of 50-60 years compared to the 30-to 39-year-old women (adjusted HR 3.13; 95% CI 1.70-5.74). The likelihood of persistent infection increased with the viral load at baseline; the adjusted HR being 3.29 (95% CI 2.21-4.90) for RLU 100, followed by 2.69 (95% CI 1.71-4.22) for RLU 10-100. Other characteristics such as education, marital status, age at marriage, number of pregnancies and menopausal status were not associated with HPV persistence ( Table 2 ). The risk of HPV persistence in the women with normal baseline diagnosis was similar to that in the women with CIN1.
Cumulative incidence of CIN21 in the HPV-positive women
The overall mean follow-up time of the 650 HR-HPVpositive women with normal or CIN1 diagnosis at baseline was 2.1 PYO (range 0.1-5.1). During the follow-up, 41 (6.3%) women progressed to CIN21 disease (CIN2: 28, CIN3: 11 and invasive cancers: 2). The two cancers were diagnosed at stages Ia1 (microinvasive) and Ib1, respectively, according to the staging classification of International Federation of Gynecologists & Obstetricians (FIGO). Table 3 shows the association between the characteristics of the women and the risk of progression to CIN21. The overall incidence rate of CIN21 was 3.0/100 PYO after a baseline positive HPV test. When stratified by age, the incidence rate of CIN21 was observed to be the highest (9.7/100 PYO) in women above 50 years of age as compared to the younger women (adjusted HR 4.32; 95% CI 1.05-17.74). Other than the age, persistence of HPV infection was the most important characteristic to influence the incidence rate ofCIN21. The incidence rate of CIN21 in women with persistent infection was 9.9/100 PYO with an adjusted HR of 6.28 (95% CI 2.87-13.73).Of the women who had persistent infection, 8.1% (13/160) developed CIN3 or worse disease (CIN31). On the other hand, no CIN31 was detected among women who cleared HPV infection during the follow-up and only 1.7% of them had a subsequent diagnosis of CIN2. Viral load did not have any significant influence on disease progression. However, we observed that the women who had rising viral load evident by an increasing RLU/PC cutoff had significantly higher risk of developing CIN21 compared to those with diminishing values (20.9% vs 4.8%; p < 0.001) 
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Cumulative incidence of CIN21 in women with CIN1 at baseline A total of 177 women with histopathology-proved CIN1 were followed up for a mean 2.0 PYO (range 0.6-5.0) and disease progression was observed in 27 (15.3%) women (incidence rate 7.7/100 PYO). Higher age at detection and HPV persistence were the only significant factors that influenced progression (Table 4) .
Baseline colposcopic diagnosis and risk of progression
Among the included women, baseline colposcopy suspected low-grade lesions in 155 (23.8%) and high-grade lesion in 19 (2.9%) women. Histopathology-proved CIN21 were detected at follow-up in 7.7% women with a colposcopic diagnosis of low-grade lesions and 26.4% women with a diagnosis of high-grade lesions at baseline. Only 5% of the women with normal colposcopy at baseline were detected to have CIN21 on follow-up. The sensitivity and specificity of baseline colposcopy to detect CIN21 lesions in the follow-up cohort were 41.5% (95% CI 26.3-57.9) and 74.2 (95% CI 70.6-77.6).
Discussion
Our study prospectively assessed a subset of women who were HR-HPV-positive but did not have histopathologically detectable cervical high-grade disease or cancer at baseline. The study endpoint was development of CIN21 at any of the follow-up visits. We used HCII test to detect HR-HPV for screening as well as for follow-up of the women. Although the test does not specify the type of HPV infection, it quantifies the viral load, which was assessed for its significance in the development of high-grade cervical neoplasia. Although a single positive HR-HPV test is predictive of future risk of CIN21, most of the test-positive women in a screened population will not develop the disease. In our study, we used repeat HPV testing along with colposcopy and biopsy to do risk stratification and identify the women who were at highest risk of developing the disease. We defined persistent infection as presence of HR-HPV infection in cervical samples throughout the follow-up period. Similar to previous studies by different authors, [8] [9] [10] our study observed that the cumulative incidence of CIN21 was significantly higher in women who had persistent HR-HPV infection compared to those who cleared the infection. Our results were consistent with the Danish study, 11 in which CIN21 were detected after 3 years in 6.3% of the high-risk HPV-positive women who were initially cytologically negative. However, it is possible that some of the CIN21 detected at follow-up were prevalent lesions that were missed by colposcopy and biopsy. There were two cases of invasive cancer: one case of squamous cell carcinoma in a 54-year-old woman detected at 26 months of follow-up and one case of adenoma malignum in a 32-year-old woman detected at 27 months of follow-up; the possibility of misdiagnosis by the colposcopist in both the cases cannot be ruled out. Earlier studies have observed that the cumulative incidence rate of CIN21 in HPV-positive women increases with advancing age, infection with HPV 16 and longer duration of follow-up. [12] [13] [14] [15] [16] In our study, the rate of viral persistence in the 50-to 60-year-old women was 3 times higher compared to 30-to 39-year-old women. Out of the 41 women who showed disease progression to CIN21, 21 (51.2%) were in the age group of 50-60 years. Such observations may be explained by the fact that the infections identified in the older women are more likely to be already persistent for several years, whereas infections in the younger women are more likely to represent recently acquired infections likely to be transient. 17 In addition to age and viral persistence, the rising HPV viral load was an independent risk factor in our study. The HCII technology can perform semiquantitative estimation of viral load, which correlates well with the viral load estimated by real-time polymerase chain reaction (RT-PCR). 18 Our earlier study demonstrated the high predictive value of high viral load (100 RLU/PC cutoff estimated by HCII) to detect the prevalent CIN21. 19 Origoni et al. 20, 21 observed significant correlation between the viral load estimated by HCII with probability of CIN21 disease in patients with atypical squamous cells of undetermined significance (ASCUS) cytology. They concluded that the quantitative information on viral load (RLU/PC cutoff) could be considered as a viable tool to improve test specificity. In this study, we observed that the viral load at baseline as well as the rising viral load are highly predictive of future development of high-grade lesions in the HPV-positive women. Women who had rising viral load had four times higher risk of developing CIN21 (20.9% vs 4.8%; p < 0.001) compared to those with diminishing values and the risk of CIN31 was even greater. This finding is consistent with that of Sun et al. 22 and Josefsson et al. 23 A recent study 24 has shown that there is a steady increase in viral load prior to development of high-grade cervical neoplasia suggesting that increasing viral load over time may be used to predict the high-grade cervical neoplasia before it develops to cervical cancer. Our results were contradicted by Clavel et al. 25 and Lorincz et al. 26 who concluded that the viral load estimation of HR-HPVs as determined by HCII test was not a sensitive approach to predict the future risk of high-grade cervical neoplasia. However, the first study had very low sample size and limited follow-up while the second study used cervicovaginal lavage to estimate the viral load and these factors could have influenced their results.
Interestingly, 75% (21/28) of the women detected to have CIN2 at follow-up had reduction in viral load compared to the baseline values. It is possible that these lesions would have regressed without treatment. CIN2 detection by histopathology has a lot of interobserver variability and the possibility of misclassification of the disease cannot be ruled out. 27 Our results corroborate the observations from the ASCUS-LSIL Triage Study (ALTS) Group that the risk of subsequent CIN21 among the women with CIN1 is the same as that of the women with negative colposcopy and directed biopsy. 28 The risks of HPV persistence and subsequent CIN21 in the Infectious Causes of Cancer 
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women with baseline CIN1 diagnosis in our study were no different from the women with no disease (adjusted HR 1.19; 95% CI 0.85-1.66 and 1.22; 95% CI 0.60-2.46, respectively). Large majority of the CIN1 lesions will not progress further even if they are HPV positive and they should be followed up exactly like the HPV-positive women with normal cervix. The major limitation of our study was the high number of women who could not be followed up. In spite of developing a system of actively tracking the women for the study purpose, the follow-up coverage was low. Convincing women to attend clinics for repeat follow-up visits at yearly interval was a challenging task, particularly because they were asymptomatic and a proportion of them had normal histopathology. Our earlier study demonstrated the low compliance of the population to cervical cancer screening and follow-up due to the fear of getting cancer diagnosis, fatalistic attitude and poor empowerment of the women. 29 However, the compliant and the noncompliant groups were similar in their baseline sociodemographic parameters (Table 1 ) and it is unlikely that inclusion of the noncompliant group would have significantly changed the results.
The strength of our study was that all the screening and diagnostic tests were done in the community setting. This allowed the study findings to be translatable to the population at large. Moreover, majority of the baseline diagnoses and all the follow-up diagnoses were established on histopathology even for the normal women, which gives high validity to the results.
Our study concluded that nearly three-fourth of the HR-HPV-positive women in whom colposcopy and biopsy have excluded high-grade lesions clear the infection within a relatively short period of time and the women clearing the infections have extremely low risk of developing CIN31 disease. This is applicable even if the histopathology at baseline is CIN1. In this subgroup the elderly women, the women with high viral load at baseline and those with rising viral load have higher risk of viral persistence and a risk-based strategy for follow-up may be considered.
